A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Prospectively Identified 11q-Deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) or B Cell Lymphomas.

Trial Profile

A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Prospectively Identified 11q-Deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), Prolymphocytic Leukaemia (PLL) or B Cell Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2014

At a glance

  • Drugs AZD 6738 (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Lymphoid leukaemia
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Jul 2014 Last checked against the ClinicalTrials.gov record.
    • 18 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top